Targeting LDHA Palmitoylation Sensitizes GBM to Chemoradiotherapy via Suppressing Palmitic Acid Induced Glycolytic Reprogramming.

Authors

Zijie Gao, Rongrong Zhao, Zheyuan Chen, Qingtong Wang, Huanyu Yang, Boyan Li, Yanhua Qi, Shulin Zhao, Jixing Zhao, Jiawei Qiu, Ziwen Pan, Zhe Han, Ruochuan Li, Huize Xia, Weijie Tang, Xing Guo, Ping Zhang, Hongyu Zhao, Xu Qian, Gang Li, Hao Xue

Published in

Advanced science (Weinheim, Baden-Wurttemberg, Germany). Pages e77536. Sep 28, 2026. Epub Sep 28, 2026.

Abstract

Glioblastoma (GBM) is a lethal malignancy characterized by therapeutic resistance and recurrence, which are driven by dynamic cellular metabolic adaptation within the tumor microenvironment. However, the precise molecular metabolic mechanisms remain poorly understood. Here, we found that palmitic acid (PA) accumulates in hypoxic pseudopalisading regions of GBM and drives the formation of mesenchymal (MES) GBM and the hypoxia myeloid-derived macrophages (MDM) subpopulation, establishing an interactive tumor-promoting niche that fuels GBM recurrence. Maechanistically, PA induces ZDHHC12-mediated palmitoylation of lactate dehydrogenase A (LDHA) at cysteine 163. This enhances LDHA enzymatic activity, promoting glycolytic reprogramming that reinforces the MES phenotype and confers resistance to chemoradiotherapy. Concurrently, palmitoylation facilitates the exosomal sorting of LDHA, which is internalized by MDMs, inducing their polarization into an immunosuppressive, glycolytic hypoxia-MDM subset, which cooperatively shapes an immunosuppressive pseudopalisading niche with MES glioma stem cells to promote GBM recurrence. Critically, we identified the small molecule Rutin as a potent inhibitor of LDHA-Cys163 palmitoylation, thereby re-sensitizing GBM to chemoradiotherapy. This study defines a metabolic circuit in recurrent GBM driven by crosstalk between PA-activated MES-GBM cells and hypoxia-MDMs. The small molecule Rutin disrupts this circuit, re-sensitizing GBM to chemoradiotherapy and offering a promising strategy to overcome post-treatment recurrence.

PMID:
42803511
Bibliographic data and abstract were imported from PubMed on 28 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.